Ethyl 4-chloro-8-(trifluoromethoxy)quinoline-3-carboxylate | 1040013-63-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: Ethyl 4-chloro-8-(trifluoromethoxy)quinoline-3-carboxylate
• CAS: 1040013-63-5
• 化学式: C₁₃H₉ClF₃NO₃
• 分子量: 319.66
• InChiKey: XDUCCTPHMSLSKV-UHFFFAOYSA-N

物化性质

• 沸点：
  333.9±37.0 °C(Predicted)
• 密度：
  1.430±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Ethyl 4-chloro-8-(trifluoromethoxy)quinoline-3-carboxylate 、 环戊胺 以to afford 4-cyclopentylamino-8-trifluoromethoxy-quinoline-3-carboxylic acid ethyl ester (220 mg)的产率得到4-cyclopentylamino-8-trifluoromethoxy-quinoline-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors

  摘要：

  本发明涉及公式（I）所定义的化合物、制药组合物及其在治疗由TNF-α或PDE4介导的疾病或障碍，包括但不限于类风湿性关节炎的使用方法。

  公开号：

  US09393245B2

文献信息

• [EN] TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-a SYNTHESIS AND AS PDE4 INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE LA SYNTHÈSE DE TNF-? ET EN TANT QU'INHIBITEURS DE PDE4
  申请人：HIGH POINT PHARMACEUTICALS LLC

  公开号：WO2009094528A1

  公开（公告）日：2009-07-30

  The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-alpha or by PDE4, including but not limited to rheumatoid arthritis.

  本发明涉及化合物的化学式（I），如本文所定义，药物组合物以及在治疗由TNF-alpha或PDE4介导的疾病或疾病中的使用方法，包括但不限于类风湿关节炎。
• Tricyclic Compounds As Modulators of TNF-alpha Synthesis
  申请人：Mjalli Adnan M. M.

  公开号：US20100190808A1

  公开（公告）日：2010-07-29

  The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-alpha or by PDE4, including but not limited to rheumatoid arthritis.

  本发明涉及公式(I)所定义的化合物、药物组合物以及在治疗由TNF-alpha或PDE4介导的疾病或疾病中使用的方法，包括但不限于类风湿关节炎。
• Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors
  申请人：Mjalli Adnan M.M.

  公开号：US20110160234A1

  公开（公告）日：2011-06-30

  The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4, including but not limited to rheumatoid arthritis.

  本发明涉及化学式（I）所定义的化合物，制药组合物以及在治疗由TNF-α或PDE4介导的疾病或疾病中使用的方法，包括但不限于类风湿性关节炎。
• Tricyclic compounds as modulators of TNF-α synthesis
  申请人：High Point Pharmaceuticals, LLC

  公开号：US07964608B2

  公开（公告）日：2011-06-21

  The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-alpha or by PDE4, including but not limited to rheumatoid arthritis.

  本发明涉及式（I）所定义的化合物、制药组合物以及在治疗由TNF-alpha或PDE4介导的疾病或疾病中使用的方法，包括但不限于类风湿性关节炎。
• Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors
  申请人：High Point Pharmaceuticals, LLC

  公开号：US08329715B2

  公开（公告）日：2012-12-11

  The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4, including but not limited to rheumatoid arthritis.

  本发明涉及化学式（I）所定义的化合物、制药组合物以及在治疗由TNF-α或PDE4介导的疾病或疾病中的使用方法，包括但不限于类风湿性关节炎。